The biggest semaglutide adults over 65 study to date has now landed, and it answers the question every primary care doctor in America has been quietly asked for two years: does Ozempic actually work — and stay safe — in older patients? The short answer from the European Congress on Obesity 2026 is yes, with caveats worth understanding.
A pooled analysis of six STEP trials, led by Prof. Luca Busetto at the University of Padova, followed 358 adults aged 65 and older (mean age 69, mean BMI 36.6) and found average body-weight reductions of 15.4% at 68 weeks on once-weekly semaglutide 2.4 mg — compared with 5.1% in the placebo arm. For a population historically underrepresented in obesity drug trials, that is a landmark result. Here’s what it means, who shouldn’t take it, and what to ask your doctor before considering a prescription.
What the semaglutide adults over 65 study actually found
The analysis pooled data from six trials in Novo Nordisk’s STEP program — the same trial family that produced the original semaglutide weight-loss approval. Researchers extracted everyone aged 65 or older without diabetes and tracked them through 68 weeks (roughly 16 months). The headline number — 15.4% average body-weight loss — is essentially identical to what younger adults experience on the same dose.
Cardiometabolic markers improved too: blood pressure dropped, waist circumference shrank, lipid profiles got better, and HbA1c (a measure of long-term blood sugar) trended down even in people without diabetes. None of those endpoints reached the importance of the primary weight result, but together they support the case for treating obesity as a chronic disease in older adults rather than writing it off as “just aging.”
Why this study matters for older adults
Adults over 65 carry a disproportionate share of obesity-related disease — type 2 diabetes, cardiovascular disease, osteoarthritis, certain cancers — yet most prior GLP-1 trials had so few older participants that doctors were prescribing largely on extrapolation. The new analysis closes that evidence gap with hard numbers in the population most likely to benefit.
It also speaks to a quieter clinical worry: that older adults losing 15% of their body weight might lose disproportionate muscle mass and worsen frailty. The STEP subgroup analysis didn’t see signal for that outcome, though Busetto’s team noted that body-composition imaging in a future study should confirm whether lean mass is being preserved.
The safety profile you should know about
Side effects in adults over 65 looked similar to younger patients — nausea, vomiting, occasional GI upset — but were slightly more common and more likely to cause discontinuation. Roughly 6% of older participants stopped the drug because of side effects compared with about 4% in the broader STEP population.
The more important caveats are clinical, not statistical. Semaglutide should not be combined with sulfonylureas or insulin in older adults without close monitoring, because the hypoglycemia risk compounds. Patients with a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia type 2 should not take it at any age. And anyone scheduled for surgery should discuss timing with their physician — recent FDA labeling updates flagged anesthesia risks tied to delayed gastric emptying.
What to ask your doctor before considering Ozempic over 65
Bring four questions to the appointment. What is my baseline kidney function (eGFR)? Am I on any medications that interact with GLP-1 agonists? What is my muscle mass status, and how will we monitor it during weight loss? And — practically — does my insurance cover this for weight management, or only for diabetes?
That last question matters because the coverage landscape in 2026 is still fragmented. Medicare Part D does not cover semaglutide for weight loss in most plans, only for type 2 diabetes. Out-of-pocket cost for Wegovy or Ozempic prescribed off-label for weight management can exceed $1,000 per month, which makes the new STEP data more about clinical guidance than immediate access for many older Americans.
What’s next for GLP-1s in older adults
Two trials worth tracking: a dedicated SELECT-Older substudy looking at cardiovascular outcomes in people 70+, and a head-to-head trial of semaglutide versus tirzepatide (Mounjaro, Zepbound) in adults 65 and up. Results from both are expected in late 2026 or early 2027.
For now, the message is straightforward: semaglutide works in older adults, with the same magnitude of benefit and a similar but slightly elevated side-effect profile compared to younger patients. The question of access — and whether Medicare will broaden coverage — is the next fight.
For related reading, see our coverage of the exercise-and-chronic-disease study and our May 2026 health roundup. Stay tuned to USA Neo News for daily evidence-based health coverage.
Sources: ScienceDaily, Medscape. This article is for informational purposes only and is not medical advice. Consult your physician before starting, stopping, or changing any prescription medication.
